Overview
Eli Lilly and Company discovers, develops, manufactures and sells medicines in diabetes, oncology, immunology, neuroscience and other areas from its base in Indianapolis, where Forbes records it was founded by Eli Lilly in 1876.[2] Its Forbes sales of US$72.3bn compare with US$45.0bn in the prior-year column, a rise of 60.4% that lifted it from tenth to third place among the companies in this list.[2] No other company in the top 25 grew by more than about 21% on the same basis. Lilly is also the most profitable company here, with US$25.3bn of profit, and the most valuable: Forbes puts its market value at US$946.4bn, more than any other pharmaceutical company and more than the next two companies combined.[2] The growth reflects demand for its diabetes and obesity treatments, a market it shares with Novo Nordisk, which ranks tenth.
Eli Lilly strengths and limitations
Strengths
- Fastest sales growth in the top 25
- Highest profit and market value in the list
- Focused, single-segment business
Limitations
- Revenue is concentrated in one therapy area
- Valuation implies high expectations
- Faces direct competition from Novo Nordisk and new entrants
Appears in
Eli Lilly peers and competitors
Companies ranked in the same lists as Eli Lilly.
Johnson & Johnson
Takeda Pharmaceutical
Daiichi Sankyo- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences- Amgen
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.